Sanofi Wins Appeal Ruling Upholding Patent on Jevtana (2)

Sanofi patent on prostate-cancer drug expiring in 2021 was correctly upheld by trial court, U.S. Court of Appeals for the Federal Circuit said Aug. 14 in an opinion posted on its electronic docket.

• Generic-drug makers including Fresenius, Mylan, Apotex lose bid to invalidate patent covering the cabazitaxel compound and related pharmaceutical compositions
• Part of the appeal involving a second patent, which expires in 2031, was dismissed after appeals court said there was no longer a dispute over those patent claims
• NOTE: Sanofi dropped those claims as part of a review of the overall patent at the Patent Trial and Appeal ...